View Filing Data

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2018 shares
Document And Entity Information
Entity Registrant Name	BioLineRx Ltd.
Entity Central Index Key	0001498403
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding	114,933,144
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 3,404	$ 5,110
Short-term bank deposits	26,747	44,373
Prepaid expenses	488	307
Other receivables	1,339	586
Total current assets	31,978	50,376
NON-CURRENT ASSETS
Long-term prepaid expenses	56	61
Long-term investment		1,000
Property and equipment, net	2,227	2,505
Intangible assets, net	21,972	7,023
Total non-current assets	24,255	10,589
Total assets	56,233	60,965
CURRENT LIABILITIES
Current maturities of long-term loans	895	93
Accounts payable and accruals:
Trade	4,493	5,516
Other	1,363	1,113
Total current liabilities	6,751	6,722
NON-CURRENT LIABILITIES
Long-term loans, net of current maturities	7,838	157
Warrants	323	1,205
Total non-current liabilities	8,161	1,362
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities	14,912	8,084
EQUITY
Ordinary shares	3,110	2,836
Share premium	250,192	240,682
Capital reserve	11,955	10,337
Other comprehensive loss	(1,416)	(1,416)
Accumulated deficit	(222,520)	(199,558)
Total equity	41,321	52,881
Total liabilities and equity	$ 56,233	$ 60,965

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
RESEARCH AND DEVELOPMENT EXPENSES	$ (19,808)	$ (19,510)	$ (11,177)
SALES AND MARKETING EXPENSES	(1,362)	(1,693)	(1,352)
GENERAL AND ADMINISTRATIVE EXPENSES	(4,435)	(4,037)	(3,984)
OPERATING LOSS	(25,605)	(25,240)	(16,513)
NON-OPERATING INCOME (EXPENSES), NET	2,397	(260)	214
FINANCIAL INCOME	719	1,169	480
FINANCIAL EXPENSES	(473)	(21)	(22)
NET LOSS AND COMPREHENSIVE LOSS	$ (22,962)	$ (24,352)	$ (15,841)
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	$ (0.21)	$ (0.27)	$ (0.28)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	108,595,702	89,970,713	56,144,727

STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Ordinary shares [Member]	Share premium [Member]	Capital reserves [Member]	Other comprehensive loss [Member]	Accumulated deficit [Member]	Total
BALANCE at Dec. 31, 2015	$ 1,455	$ 196,201	$ 10,735	$ (1,416)	$ (159,365)	$ 47,610
CHANGES IN
Issuance of share capital, net	57	2,126				2,183
Employee stock options exercised	1	171	(172)
Employee stock options expired		1,069	(1,069)
Share-based compensation			1,075			1,075
Comprehensive loss for the year					(15,841)	(15,841)
BALANCE at Dec. 31, 2016	1,513	199,567	10,569	(1,416)	(175,206)	35,027
CHANGES IN
Issuance of share capital, net	1,322	39,376				40,698
Employee stock options exercised	1	328	(329)
Employee stock options expired		1,411	(1,411)
Share-based compensation			1,508			1,508
Comprehensive loss for the year					(24,352)	(24,352)
BALANCE at Dec. 31, 2017	2,836	240,682	10,337	(1,416)	(199,558)	52,881
CHANGES IN
Issuance of share capital, net	263	8,567				8,830
Employee stock options exercised	11	415	(380)			(46)
Employee stock options expired		528	(528)
Share-based compensation			2,526			2,526
Comprehensive loss for the year					(22,962)	(22,962)
BALANCE at Dec. 31, 2018	$ 3,110	$ 250,192	$ 11,955	$ (1,416)	$ (222,520)	$ 41,321

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2018-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=7&date=2018-03-01&anchor=para_18_b&doctype=Standard
-URIDate 2018-03-16

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_24_b&doctype=Standard
-URIDate 2018-03-16

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2018-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=1&date=2018-03-01&anchor=para_32_a_ii&doctype=Standard
-URIDate 2018-03-16

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_28_b&doctype=Standard
-URIDate 2018-03-16

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2018-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=4&date=2018-03-02&anchor=para_39L_e&doctype=Standard&book=b
-URIDate 2018-03-16

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_23&doctype=Standard
-URIDate 2018-03-16

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2018-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2018-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2018-03-16

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_106_d_i&doctype=Standard
-URIDate 2018-03-16

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2018-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=17&date=2018-03-01&anchor=para_113_b&doctype=Standard
-URIDate 2018-03-16

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_81A_a&doctype=Standard
-URIDate 2018-03-16

+ Details

CONSOLIDATED CASH FLOW STATEMENTS - USD ($) $ in Thousands	12 Months Ended
CONSOLIDATED CASH FLOW STATEMENTS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS - OPERATING ACTIVITIES
Net loss	$ (22,962)	$ (24,352)	$ (15,841)
Adjustments required to reflect net cash used in operating activities (see appendix below)	(1,230)	3,805	1,328
Net cash used in operating activities	(24,192)	(20,547)	(14,513)
CASH FLOWS - INVESTING ACTIVITIES
Increase in long-term investment		(1,000)
Realization of long-term investment	1,500
Investments in short-term deposits	(26,500)	(44,016)	(32,982)
Maturities of short-term deposits	44,771	33,327	42,334
Purchase of property and equipment	(173)	(338)	(52)
Purchase of intangible assets	(10,043)	(3,900)	(3)
Net cash provided by (used in) investing activities	9,555	(15,927)	9,297
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital and warrants, net of issuance costs	3,830	38,773	2,183
Employee stock options exercised	46
Proceeds of long-term loan and warrants, net of issuance costs	9,632
Repayment of long-term loan	(318)
Repayments of bank loan	(93)	(93)	(93)
Net cash provided by financing activities	13,097	38,680	2,090
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(1,540)	2,206	(3,126)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	5,110	2,469	5,544
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(166)	435	51
CASH AND CASH EQUIVALENTS - END OF YEAR	3,404	5,110	2,469
Income and expenses not involving cash flows:
Depreciation and amortization	545	481	482
Long-term prepaid expenses	5	(9)	6
Exchange differences on cash and cash equivalents	166	(435)	(51)
Loss (gain) on adjustment of warrants to fair value	(1,743)	127	(207)
Share-based compensation	2,526	1,508	1,075
Interest and exchange differences on short-term deposits	(645)	(530)	(387)
Interest and linkage differences on loans	123		(1)
Gain on realization of long-term investment	(500)
Warrant issuance costs		17
Total income and expense not involving cash flows	477	1,159	917
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses and other receivables	(934)	(415)	42
Increase (decrease) in accounts payable and accruals	(773)	3,061	369
Total Change in operating asset and liability	(1,707)	2,646	411
Total Adjustments required to reflect net cash used in operating acivities	(1,230)	3,805	1,328
Supplementary information on investing and financing activities not involving cash flows:
Supplemental information on interest received in cash	834	494	453
Supplemental information on non-cash transactions (see Notes 18 and 19)	$ 5,000	$ 2,985

GENERAL INFORMATION

12 Months Ended

Dec. 31, 2018

Disclosure of general information [Abstract]

GENERAL INFORMATION

NOTE 1 – GENERAL INFORMATION

General

BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.

BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical stages, with a focus on the field of oncology.

In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market.

In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology. See Note 17.

Although the Company has generated revenues from out-licensing transactions in the past, the Company cannot determine with reasonable certainty when and if it will have sustainable profits.

Approval of consolidated financial statements

The consolidated financial statements of the Company for the year ended December 31, 2018 were approved by the Board of Directors on March 25, 2019, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2018

Disclosure of significant accounting policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The Company’s consolidated financial statements as of December 31, 2018 and 2017, and for each of the three years in the period ended December 31, 2018, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). The significant accounting policies described below have been applied on a consistent basis for all years presented, unless noted otherwise.

The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss.

The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company’s accounting policies. Areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are disclosed in Note 4. Actual results may differ materially from estimates and assumptions used by the Company’s management.

Principles of consolidation

Consolidated entities are all entities over which BioLineRx has control. BioLineRx controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidated entities are fully consolidated from the date on which control of such entities is transferred to BioLineRx and they are de-consolidated from the date that control ceases.

Functional and reporting currency

The functional and reporting currency in these financial statements is the U.S. dollar (“dollar”, “USD” or “$”), which is the primary currency of the economic environment in which the Company operates. Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognized in profit or loss.

Foreign exchange gains and losses that relate to borrowings are presented in the statement of comprehensive loss, within financial expenses. All other foreign exchange gains and losses are presented in the statement of comprehensive loss on a net basis within non-operating income or expenses.

Cash equivalents and short-term bank deposits

Cash and cash equivalents include cash on hand and short-term bank deposits (up to three months from date of deposit) that are not restricted as to withdrawal or use, and are therefore considered to be cash equivalents. Bank deposits with original maturity dates of more than three months and with a current maturity date of less than one year from the balance sheet date are included in short-term bank deposits. The fair value of cash equivalents and short-term bank deposits approximate their carrying value, since they bear interest at rates close to the prevailing market rates. See also Note 6.

Property and equipment

Property and equipment are stated at historical cost less depreciation. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Assets are depreciated by the straight-line method over the estimated useful lives of the assets, provided that the Company’s management believes the residual values of the assets to be negligible, as follows:

	%
Computers and communications equipment		20-33
Office furniture and equipment		6-15
Laboratory equipment		15-20

The assets’ residual values, methods of depreciation and useful lives are reviewed and adjusted, if appropriate, at each balance sheet date. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount.

Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.

Intangible assets

The Company applies the cost method of accounting for initial and subsequent measurements of intangible assets. Under this method of accounting, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses.

Intellectual property

The Company recognizes in its financial statements intangible assets developed by the Company to the extent that the conditions stipulated in n. below are met. Intellectual property acquired by the Company is initially measured at cost. Intellectual property acquired by the Company for development purposes is not amortized and is tested annually for impairment. See g. below.

Computer software

Acquired computer software licenses are capitalized on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortized over the estimated useful lives of the software (3-5 years).

Impairment of non-financial assets

Impairment of intellectual property is required when the Company decides to terminate or suspend the development of a project based on such intellectual property. In addition, the Company performs impairment reviews on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. Property and equipment, as well as computer software, are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized equal to the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and the asset’s value in use to the Company.

Financial assets

Effective January 1, 2018, the Company adopted IFRS 9 “Financial Instruments.”

Classification

The financial assets of the Company are classified into the following two categories:
(i) financial assets at fair value through profit or loss, and (ii) financial assets at amortized cost. The classification is done on the basis of the Company’s business model for managing the financial assets and the contractual cash flow characteristics of the financial assets.

Financial assets at amortized cost

Financial assets at amortized cost are assets held pursuant to a business model whose objective is to hold assets in order to collect contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets at amortized cost are included in current assets, except for those with maturities greater than 12 months after the balance sheet date (in which case they are classified as non-current assets).

The Company’s financial assets at amortized cost are included in other receivables and bank deposits in the consolidated statements of financial position.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are assets not measured at amortized cost in accordance with (1)(a) above. Assets in this category are classified as current assets if they are expected to be settled within 12 months; otherwise, they are classified as non-current assets.

Recognition and measurement

Regular purchases and sales of financial assets are recognized on the settlement date, which is the date on which the asset is delivered to the Company or delivered by the Company. Investments are initially recognized at fair value plus transaction costs for all financial assets not recorded at fair value through profit or loss, except for trade receivables, which are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components.

Financial assets measured at fair value through profit or loss are initially recognized at fair value, and related transaction costs are expensed to profit or loss. Financial assets are derecognized when the rights to receive cash flow from the investments have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets at fair value through profit or loss are subsequently recorded at fair value. Financial assets at amortized cost are measured in subsequent periods at amortized cost using the effective interest method. Gains or losses arising from changes in the fair value of financial assets at fair value through profit or loss are presented in the Statement of Comprehensive Loss under financial income or expenses.

Impairment

The Company recognizes a loss allowance for expected credit losses on financial assets at amortized cost. At each reporting date, the Company assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. If the financial instrument is determined to have low credit risk at the reporting date, the Company assumes that the credit risk on a financial instrument has not increased significantly since initial recognition.

Prior to the effective date and adoption of IFRS 9, the financial assets of the Company were classified into the following categories: (i) financial assets at fair value through profit or loss, and (ii) loans and receivables. The classification depended on the purpose for which the financial assets were acquired. Also, prior to the adoption of IFRS 9, the Company assessed at December 31, 2017 whether there was any objective evidence that a financial asset or group of financial assets was impaired.

Warrants

Receipts in respect of warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price is not deemed to be fixed, the warrants are classified as a non-current derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. The fair value changes are charged to non-operating income and expense on the statement of comprehensive loss. Issuance costs allocable to warrants are also recorded as non-operating expense on the statement of comprehensive loss.

Share capital

The Company’s ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of new shares are shown in equity as a deduction from the issuance proceeds.

Trade payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. These payables are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method.

Deferred taxes

Deferred taxes are recognized using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax assets are recognized only to the extent that it is probable that future taxable income will be available against which the temporary differences can be utilized.

As the Company is currently engaged primarily in development activities and is not expected to generate taxable income in the foreseeable future, no deferred tax assets are included in the financial statements.

Revenue from contract with customers

Effective January 1, 2018, the Company adopted IFRS 15, “Revenue from Contracts with Customers.”

IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:

identify the contract with a customer;

identify the performance obligations in the contract;

determine the transaction price;

allocate the transaction price to the performance obligations in the contract; and

recognize revenue when (or as) the entity satisfies a performance obligation.

During the reported years, the Company did not generate revenues, other than immaterial amounts received from an out-licensing agreement signed in 2014 with Perrigo Company plc., which have been included as non-operating income.

Research and development expenses

Research expenses are charged to profit or loss as incurred.

An intangible asset arising from development (or from the development phase of an internal project) is recognized if all of the following conditions are fulfilled:

technological feasibility exists for completing development of the intangible asset so that it will be available for use or sale.

it is management’s intention to complete development of the intangible asset for use or sale.

the Company has the ability to use or sell the intangible asset.

it is probable that the intangible asset will generate future economic benefits, including existence of a market for the output of the intangible asset or the intangible asset itself or, if the intangible asset is to be used internally, the usefulness of the intangible asset.

adequate technical, financial and other resources are available to complete development of the intangible asset, as well as the use or sale thereof.

the Company has the ability to reliably measure the expenditure attributable to the intangible asset during its development.

Other development costs that do not meet the foregoing conditions are charged to profit or loss as incurred. Development costs previously expensed are not recognized as an asset in subsequent periods. As of December 31, 2018, the Company has not yet capitalized development expenses.

Employee benefits

Pension and severance pay obligations

Israeli labor laws and the Company’s employment agreements require the Company to pay retirement benefits to employees terminated or leaving their employment in certain other circumstances. Most of the Company’s employees are covered by a defined contribution plan under Section 14 of the Israel Severance Pay Law.

With respect to the remaining employees, the Company records a liability on its balance sheet for defined benefit plans that represents the present value of the defined benefit obligation as of each reporting date, net of the fair value of plan assets. The present value of the defined benefit liability is determined by discounting the anticipated future cash outflows, using interest rates that are denominated in the currency in which the benefits will be payable.

The amounts recorded as an employee benefit expense in respect of pension and severance pay obligations for the years 2016, 2017 and 2018 were $523,000, $563,000 and $618,000 respectively.

Vacation and recreation pay

Labor laws in Israel entitle every employee to vacation and recreation pay, both of which are computed annually. The entitlement with respect to each employee is based on the employee’s length of service at the Company. The Company recognizes a liability and an expense in respect of vacation and recreation pay based on the individual entitlement of each employee.

Share-based payments

The Company operates an equity-settled, share-based compensation plan, under which it grants equity instruments (options, restricted stock units and performance stock units) of the Company as additional consideration for services from employees. The fair value of the employee services received in exchange for grant of the equity instruments is recognized as an expense. The total amount to be expensed is determined by reference to the fair value of the equity instruments granted:

including any market performance conditions (for example, the Company’s share price); and

excluding the impact of any service and non-market performance vesting conditions (for example, profitability, sales growth targets and the employee remaining with the entity over a specified time period).

Non-market performance and service conditions are included in assumptions about the number of equity instruments that are expected to vest. The total expense is recognized over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

When the equity instruments are exercised, the Company issues new shares. The proceeds received, net of any directly attributable transaction costs, are credited to share capital (at par value) and share premium when the equity instruments are exercised.

Loss per share

Basic

The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year.

Diluted

The diluted loss per share is calculated by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all dilutive potential shares. The Company’s dilutive potential shares consist of warrants issued to investors, as well as equity instruments granted to employees and service providers. The dilutive potential shares were not taken into account in computing loss per share in 2016, 2017 and 2018, as their effect would have been anti-dilutive.

Standards and interpretations to existing standards that are not yet in effect and have not been early adopted by the Company

International Financial Reporting Standard No. 16 “Leases” (“IFRS 16”)

IFRS 16 was issued in January 2016, sets out principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract, and replaces the previous lease standard, IAS 17, “Leases.” IFRS 16 eliminates the classification of leases for the lessee as either operating leases or finance leases as required by IAS 17, and instead introduces a single lessee accounting model whereby a lessee is required to recognize assets and liabilities for all leases with a term that is greater than 12 months, unless the underlying asset is of low value, and to recognize amortization of lease assets separately from interest on lease liabilities in the income statement. IFRS 16 is effective from January 1, 2019.

The Company intends to apply the new standard from its mandatory adoption date of January 1, 2019, using the simplified transition approach without restating comparative amounts for the year prior to first adoption.

The Company has reviewed all of its leasing arrangements outstanding as of December 31, 2018 in light of the new lease accounting rules in IFRS 16, and has determined that the standard will affect primarily the accounting for its operating leases.

The Company expects to recognize right-of-use assets and lease liabilities of approximately $1.9 million on January 1, 2019. The Company does not expect adoption of the new standard to have a material effect on the consolidated statement of comprehensive income (loss) for 2019. The Company does expect certain changes in the consolidated cash flow statement for 2019, specifically an increase in operating cash flows of approximately $0.3 million, along with a corresponding decrease in financing cash flows, as repayment of the principal portion of the lease liabilities will be classified as cash flows from financing activities.

FINANCIAL RISK MANAGEMENT

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about financial instruments [abstract]

FINANCIAL RISK MANAGEMENT

NOTE 3 – FINANCIAL RISK MANAGEMENT

Based on assessments by Company management, the Company’s exposure to credit risk as of December 31, 2018 is immaterial (see Note 3b). The activities of the Company expose it to market risk, primarily as a result of currency risk.

The Company’s Finance Department is responsible for carrying out risk management activities in accordance with policies approved by its Board of Directors. In this regard, the Finance Department identifies, defines and assesses financial risks in close cooperation with other Company departments. The Board of Directors provides written guidelines for overall risk management, as well as written policies dealing with specific areas, such as exchange rate risk, interest rate risk, credit risk, use of financial instruments and investment of excess cash.

Market risk

Concentration of currency risk

The Company’s activities are partly denominated in non-dollar currencies (primarily the New Israeli Shekel, or “NIS,” and the Euro), which exposes the Company to risks resulting from changes in exchange rates.

The effect of fluctuations in various exchange rates on the Company’s income and equity is as follows:

	December 31, 2018
	Income (loss)						Value on			Income (loss)
Sensitive instrument	10% increase			5% increase			balance sheet			5% decrease			10% decrease
	in USD thousands
NIS-linked balances:
Cash and cash equivalents		(64	)		(33	)		699			37			78
Other receivables		(45	)		(23	)		491			26			55
Trade payables		73			38			(807	)		(42	)		(90	)
Other payables		57			30			(632	)		(33	)		(70	)
Total NIS-linked balances		21			12			(249	)		(12	)		(27	)
Euro-linked trade payables		(177	)		(93	)		(453	)		102			216
Total		(156	)		(81	)		(702	)		90			189

The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material.

	December 31, 2017
	Income (loss)						Value on			Income (loss)
Sensitive instrument	10% increase			5% increase			balance sheet			5% decrease			10% decrease
	in USD thousands
NIS-linked balances:
Cash and cash equivalents		(216	)		(113	)		2,376			125			264
Other receivables		(30	)		(15	)		325			17			36
Trade payables		69			36			(764	)		(40	)		(85	)
Other payables		69			36			(756	)		(40	)		(84	)
Total NIS-linked balances		(108	)		(56	)		1,181			62			131
Euro-linked trade payables		(94	)		(49	)		(1,031	)		(54	)		(115	)
Total		(202	)		(105	)		150			8			16

Set forth below is certain data regarding dollar exchange rates:

	Exchange rate of NIS per $1		Exchange rate of Euro per $1
As of December 31:
2016		3.845		0.951
2017		3.467		0.835
2018		3.748		0.873

Percentage increase (decrease) in:
2017		(9.8%)		(12.2%)
2018		8.1%		4.6%

Set forth below is information on the linkage of monetary items:

	December 31, 2017							December 31, 2018
	Dollar		NIS		Other currencies			Dollar		NIS			GBP and other
	USD in thousands							USD in thousands
Assets:
Current assets:
Cash and cash equivalents		2,623		2,376		111			2,274		699			431
Short term bank deposits		44,373		-		-			26,747		-			-
Other receivables		117		325		144			-		491			848
Total assets		47,113		2,701		255			29,021		1,190			1,279
Liabilities:
Current liabilities:
Current maturities of bank loan		93		-		-			895		-			-
Accounts payable and accruals:
Trade		3,018		764		1,734			2,396		807			1,290
Other		99		756		258			708		632			23
Non-current liabilities
Long-term bank loan, net of current maturities		157		-		-			7,838		-			-
		3,367		1,520		1,992			11,837		1,439			1,313
Net asset value		43,746		1,181		(1,737	)		17,184		(249	)		(34	)

Fair value of financial instruments

As of December 31, 2018, the financial instruments of the Company consist of non-derivative assets and liabilities (primarily working capital items and deposits), as well as warrants classified as a liability.

With regard to non-derivative assets and liabilities, given their nature, the fair value of the financial instruments included in working capital is generally close or identical to their carrying amount.

With regard to the warrants classified as a liability, see Notes 11c(3) and 18. With regard to the long-term loan, see Note 18.

Exposure to market risk and management thereof

In the opinion of Company management, the market risk to which the Company is exposed is primarily related to currency risk exposure, as mentioned above. Additionally, Company management does not consider the interest rate risk mentioned in paragraph 4 below to be material.

Interest rate risk

Company management does not consider interest rate risk to be material, as the Company holds deposits and short-term government bonds whose fair value and/or cash flows are not materially affected by changes in interest rates.

Credit risk

Credit risk is managed at the Company level. These risks relate to cash and cash equivalents, bank deposits and other receivables.

The Company’s cash, cash equivalents and short-term bank deposits at December 31, 2017, and 2018 were mainly deposited with highly rated major Israeli and U.S. banks. In the Company’s opinion, the credit risk associated with these balances is remote.

The Company considers its maximum exposure to credit risk to be as follows:

	December 31,
	2017		2018
	in USD thousands
Assets:
Cash and cash equivalents		5,110		3,404
Short-term bank deposits		44,373		26,747
Other receivables		586		1,339
Total		50,069		31,490

Liquidity risk

Company management monitors rolling forecasts of the Company’s liquidity reserves on the basis of anticipated cash flows and maintains the liquidity balances at a level that is sufficient to meet its needs.

Although the Company has succeeded in generating significant revenues from a number of out-licensing transactions in the past, it cannot determine with reasonable certainty if and when it will become profitable on a current basis. Management believes that the Company’s current cash (including the consideration from the offering as detailed in Note 19) and other resources will be sufficient to fund its projected cash requirements into 2021. Accordingly, in the event that the Company does not generate cash from its operating activities, the Company will need to raise additional capital in the future. Inability to raise additional capital would have a material adverse effect on the financial condition of the Company.

Fair value estimations

As described in Notes 11c(3) and 18, BioLineRx completed financing transactions in which it issued ADSs and warrants to purchase additional ADSs. The fair value of the warrants, which are not traded on an active market, is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates.

CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	12 Months Ended
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	Dec. 31, 2018
Disclosure of critical accounting estimates and judgments [Abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	NOTE 4 – CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS As part of the financial reporting process, Company management is required to make estimates that affect the value of assets, liabilities, income, expenses and certain disclosures included in the Company’s consolidated financial statements. By their very nature, such estimates are subjective and complex and consequently may differ from actual results. The accounting estimates used in the preparation of the financial statements are continually evaluated and adjusted based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. Described below are the critical accounting estimates used in the preparation of the financial statements, the formulation of which required Company management to make assumptions as to circumstances and events that involve significant uncertainty. In using its judgment to determine the accounting estimates, the Company takes into consideration, as appropriate, the relevant facts, past experience, the effect of external factors and reasonable assumptions under the circumstances. Development expenses Development expenses are capitalized in accordance with the accounting policy described in Note 2n. The capitalization of costs is based on management’s judgment of technological and economic feasibility, which is usually achieved when a development project reaches a predefined milestone, or when the Company enters into a transaction to sell the know-how that resulted from the development process. In determining the amount to be capitalized, management makes assumptions as to the future anticipated cash inflows from the assets, and the anticipated period of future benefits. Company management has concluded that, as of December 31, 2018, the foregoing conditions have not been met and therefore development expenses have not been capitalized for any project. If management had determined that the aforementioned conditions had been met, the capitalization of development costs would have resulted in an increase in the Company’s profit or a decrease in its loss. Impairment of intangible assets The Company performs impairment reviews of intangible assets on an annual basis, or more frequently if events or changes in circumstances indicate a potential impairment. In light of the clinical progress and additional expenses incurred with regard to the clinical development of BL-8040 and AGI-134, the Company has concluded that the value of its intangible assets is higher than their carrying value.

CASH AND CASH EQUIVALENTS

12 Months Ended

Dec. 31, 2018

Cash and cash equivalents [abstract]

CASH AND CASH EQUIVALENTS

NOTE 5 – CASH AND CASH EQUIVALENTS

	December 31,
	2017		2018
	in USD thousands

Cash on hand and in bank		3,960		2,329
Short-term bank deposits		1,150		1,075
		5,110		3,404

The short-term bank deposits included in cash and cash equivalents bear interest at annual rate of 0.15%. The carrying amount of cash and cash equivalents approximates their fair value, since they bear interest at rates similar to prevailing market interest rates.

SHORT-TERM BANK DEPOSITS	12 Months Ended
SHORT-TERM BANK DEPOSITS	Dec. 31, 2018
Disclosure of short-term bank deposits [Abstract]
SHORT-TERM BANK DEPOSITS	NOTE 6 – SHORT-TERM BANK DEPOSITS The short-term bank deposits are in US dollars and bear interest at annual rates of between 1.58% and 3.08%.

LONG-TERM INVESTMENT	12 Months Ended
LONG-TERM INVESTMENT	Dec. 31, 2018
Disclosure of Long-term investment [Abstract]
LONG-TERM INVESTMENT	NOTE 7 – LONG-TERM INVESTMENT In 2016, the Company established a joint venture with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China, with each party contributing initial seed capital to the venture of $1.0 million. The joint venture, named iPharma, focused on the development of innovative clinical and pre-clinical therapeutic candidates to serve the Chinese and global healthcare markets. In April 2018, the Company sold its holdings in the joint venture to I-Bridge Capital for cash consideration of $1.5 million. The gain of $0.5 million is included in non-operating income on the statement of comprehensive loss.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about property, plant and equipment [abstract]

PROPERTY AND EQUIPMENT

NOTE 8 – PROPERTY AND EQUIPMENT

Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications, as well as the changes therein for the respective years:

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2015		2016
	In USD thousands								In USD thousands								In USD thousands
Composition in 2016
Office furniture and equipment		198		-		-		198		13		12		-		25		185		173
Computers and communications equipment		446		43		-		489		355		53		-		408		91		81
Laboratory equipment		1,194		104		-		1,298		482		188		-		670		712		628
Leasehold improvements		2,025		3		-		2,028		104		201		-		305		1,921		1,723
		3,863		150		-		4,013		954		454		-		1,408		2,909		2,605

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2016		2017
	In USD thousands								In USD thousands								In USD thousands
Composition in 2017
Office furniture and equipment		198		2		-		200		25		35		-		60		173		140
Computers and communications equipment		489		266		-		755		408		30		-		438		81		317
Laboratory equipment		1,298		70		-		1,368		670		159		-		829		628		539
Leasehold improvements		2,028		-		-		2,028		305		214		-		519		1,723		1,509
		4,013		338		-		4,351		1,408		438		-		1,846		2,605		2,505

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2017		2018
	In USD thousands								In USD thousands								In USD thousands
Composition in 2018
Office furniture and equipment		200		-		-		200		60		22		-		82		140		118
Computers and communications equipment		755		9		-		764		438		60		-		498		317		266
Laboratory equipment		1,368		164		-		1,532		829		153		-		982		539		550
Leasehold improvements		2,028		-		-		2,028		519		216		-		735		1,509		1,293
		4,351		173		-		4,524		1,846		451		-		2,297		2,505		2,227

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about intangible assets [abstract]

INTANGIBLE ASSETS

NOTE 9 – INTANGIBLE ASSETS

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2015		2016
	In USD thousands								In USD thousands								In USD thousands
Composition in 2016
Intellectual property		193		-		-		193		96		-		-		96		97		97
Computer software		328		57		-		385		273		28		-		301		55		84
		521		57		-		578		369		28		-		397		152		181

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2016		2017
	In USD thousands								In USD thousands								In USD thousands
Composition in 2017
Intellectual property		193		6,703		-		6,896		96		-		-		96		97		6,800
Computer software		385		182		-		567		301		43		-		344		84		223
		578		6,885		-		7,463		397		43		-		440		181		7,023

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2017		2018
	In USD thousands								In USD thousands								In USD thousands
Composition in 2018
Intellectual property		6,896		15,000		-		21,896		96		-		-		96		6,800		21,800
Computer software		567		43		-		610		344		94		-		438		223		172
		7,463		15,043		-		22,506		440		94		-		534		7,023		21,972

LONG-TERM LOANS

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about borrowings [abstract]

LONG-TERM LOANS

NOTE 10 – LONG-TERM LOANS

Composition

	December 31,
	2017			2018
	In USD thousands

Bank loan (1)		250			156
Loan from Kreos Capital (Note 18)		-			8,577
		250			8,733
Less current maturities:
Bank loan		(93	)		(93	)
Loan from Kreos Capital		-			(802	)
Total current maturities		(93	)		(895	)
Total long-term loans		157			7,838

(1)

The loan is denominated in dollars and bears interest at an annual rate of 3.75%. The book value of the loan approximates its fair value. The loan is repayable in 60 monthly installments and is collateralized by certain lab equipment.

Future repayments

Future repayments of the long-term loans indicated above (other than current maturities) in the years subsequent to the balance sheet date are as follows:

	Bank loan		Loan from Kreos Capital		Total
	In USD thousands
2020		63		2,402		2,465
2021		-		2,892		2,892
2022		-		2,481		2,481
		63		7,775		7,838

The loan from Kreos Capital is reflected net of amounts deducted from its carrying value relating to warrants and issuance costs associated with the initial loan transaction.

EQUITY

12 Months Ended

Dec. 31, 2018

Disclosure of classes of share capital [abstract]

EQUITY

NOTE 11 – EQUITY

Share capital

As of December 31, 2017, and 2018 the Company’s share capital is composed of ordinary shares, as follows:

	Number of Ordinary Shares
	December 31,
	2017		2018

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		105,063,437		114,933,144

	In USD and NIS
	December 31,
	2017		2018

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		10,506,344		11,493,314

Issued and paid-up share capital (in USD)		2,836,139		3,109,746

As of December 31, 2018, the market price on NASDAQ of BioLineRx’s ADSs was $0.44, and the market price on the Tel Aviv Stock Exchange of BioLineRx’s ordinary shares was NIS 1.63.

Rights related to shares

The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2017 and 2018, all outstanding share capital consisted of ordinary shares.

Changes in the Company’s equity

In March 2015, the Company completed an underwritten public offering of 14,375,000 ADSs at a public offering price of $2.00 per ADS. The offering raised a total of $28.8 million, with net proceeds of approximately $26.4 million, after deducting fees and expenses.

In April 2017, the Company completed an underwritten public offering of 33,823,529 of its ADSs at a public offering price was $0.85 per ADS. The offering raised a total of $28.8 million, with net proceeds of approximately $26.2 million, after deducting fees and expenses.

In July 2017, the Company completed a direct placement to BVF Partners L.P., its largest shareholder, for aggregate gross proceeds of $9.6 million. The placement consisted of 8,495,575 ADSs, Series A warrants to purchase an additional 2,973,451 ADSs and Series B warrants to purchase an additional 2,973,451 ADSs. The Series A warrants have an exercise price of $2.00 per ADS and are exercisable for a term of four years. The Series B warrants have an exercise price of $4.00 per ADS and are also exercisable for a term of four years. Net proceeds from the transaction were approximately $9.5 million, after deducting fees and expenses.

The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss. The amount of the direct placement consideration initially allocated to the warrants was approximately $1.1 million. Total issuance costs allocable to the warrants were not material.

The fair value of the warrants is computed using the Black and Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 1.66% and an average standard deviation of 57.8%.

The fair value of the warrants as of December 31, 2018 was based on the then-current price of an ADS, a risk-free interest rate of 2.47% (December 31, 2017 - 2.09%) and an average standard deviation of 55.3% (December 31, 2017 - 56.8%).

The changes in fair value for the years ended December 31, 2017 and 2018 of approximately $100,000 and $1,200,000 has been recorded as non-operating (expense) income, respectively, on the statement of comprehensive loss.

Share purchase agreements

In May 2014, BioLineRx and Lincoln Park Capital Fund, LLC (“LPC”), entered into a $20 million, 36-month purchase agreement, together with a registration rights agreement, whereby LPC agreed to purchase, from time to time, up to $20 million of BioLineRx’s ADSs, subject to certain limitations, during the 36-month term of the purchase agreement.

In consideration for entering into the agreement, BioLineRx paid to LPC an initial commitment fee of $300,000, paid via the issuance of 150,000 ADSs, and agreed to pay a further commitment fee of up to $500,000, pro rata, as the facility was used over time, to be paid in ADSs valued based on the prevailing market prices of BioLineRx’s ADSs at such time.

In connection with the purchase agreement, BioLineRx paid an initial cash finder’s fee to Oberon Securities of $50,000, plus an additional cash finder’s fee equal to 2.0% of the dollar amount of ADSs sold under the new agreement, up to an aggregate additional finder’s fee of $200,000.

The purchase agreement with LPC expired in accordance with its terms in July 2017. On a cumulative basis, from the effective date of the purchase agreement through the date of its expiration, BioLineRx sold a total of 5,550,603 ADSs to LPC for aggregate gross proceeds of $7,000,000. In connection with these issuances, a total of 138,766 ADSs were issued to LPC as a commitment fee and a total of $140,000 was paid to Oberon Securities as a finder’s fee.

In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company may, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company will pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. From the effective date of the agreement through December 31, 2018, 5,439,203 ADSs were sold under the program for total net proceeds of approximately $5.1 million, leaving an available balance under the facility of approximately $24.9 million as of December 31, 2018.

Share-based payments

Share Incentive plan – general

In 2003, BioLineRx adopted the 2003 Share Incentive Plan (the “Plan”). The Plan provides for the granting of stock options and ordinary shares to the Company’s employees, directors, consultants and other service providers. Options are issued at the determination of the Board of Directors in accordance with applicable law. The options are generally exercisable for a ten-year period and the grants generally vest over a four-year period. In 2013, the Company’s Board of Directors approved amendments to the Plan to take into account changes in laws and regulations that had occurred since its adoption and to extend the term of the plan until November 2023. In 2016, the Board of Directors approved amendments to the Plan to allow the grant of restricted stock units (“RSUs”) and performance stock units (“PSUs”).

PSUs are RSUs that are linked to any one or more performance goals (in addition to, or in lieu of, time-based vesting terms) determined appropriate by the Board of Directors. Once vested, each PSU granted is equivalent to one ordinary share. The specific performance goals, as well as the time period associated with achieving such goals, are approved by the Board and are set forth in the grantee’s grant agreement. To date, each PSU grant has had between three to five performance goals on which vesting is based, each such goal being either a specified Company milestone and or the success of a specific project, with vesting of 20%-33% on the achievement of each goal. The tranche of PSUs associated with a given milestone expires 12 months after the target date established for that milestone. During 2018, 285,410 PSUs vested in accordance with their original terms.

As of December 31, 2018, there were 11,759,697 ordinary shares issuable upon the exercise of outstanding equity instruments under the Plan.

Ordinary shares resulting from grants under the Plan confer the same rights as all other ordinary shares of BioLineRx.

Company employees and directors are granted options under Section 102 of the Israeli Income Tax Ordinance (the “Ordinance”), primarily under the “capital gains” track. Non-employees of the Company (consultants and other service providers), as well as controlling shareholders in BioLineRx (as this term is defined in Section 32(9) of the Ordinance), are granted options under Section 3(i) of the Ordinance.

In November 2014, December 2015 and December 2017 the Company’s Board of Directors approved increases of 1.6 million, 5.0 million and 5.2 million shares, respectively, to the total pool of authorized ordinary shares reserved for purposes of the Plan and any other present or future share incentive plans of the Company, bringing the pool to an aggregate of 14.8 million shares. As of December 31, 2018, there were 1.8 million remaining authorized but unissued ordinary shares in the pool reserved for future share-based incentive grants. In March 2019, the Board approved an increase of 9.0 million shares to the pool.

Employee share incentive plan:

The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans.

	Year ended December 31,
	2016					2017					2018
	Number of options			Weighted average exercise price (in NIS)		Number of options			Weighted average exercise price (in NIS)		Number of options			Weighted average exercise price (in NIS)
Outstanding at beginning of year		3,500,262			8.7		4,557,927			6.5		10,651,097			4.4
Granted		2,505,684			3.8		7,292,560			3.5		2,853,080			2.8
Forfeited and expired		(1,435,990	)		7.2		(1,164,961	)		6.5		(1,649,090	)		4.0
Exercised		(12,029	)		0.4		(34,429	)		0.2		(395,390	)		0.4
Outstanding at end of year*		4,557,927			6.5		10,651,097			4.4		11,459,697			4.2
Exercisable at end of year		1,786,209			9.4		2,356,948			7.6		4,489,816			5.9

As of the December 31, 2016, 2017 and 2018, includes 222,428, 1,178,128 and 1,163,018 PSUs at an exercise price of 0.10 NIS (par value of ordinary shares), for which performance obligations have not been met.

The total consideration received from the exercise of equity instruments during 2016, 2017 and 2018 was not material.

Set forth below is data regarding the range of exercise prices and weighted-average remaining contractual life (in years) for the equity instruments outstanding at the end of each of the years indicated.

		Year ended December 31,
		2016				2017				2018
Range of exercise prices (in NIS)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)
Up to 5.00			1,979,244		8.2		8,642,472		8.2		9,631,342		8.2
	5.01-10.00		1,522,800		4.3		1,213,225		5.9		1,089,875		4.3
	10.01-20.00		1,037,436		2.7		795,400		4.7		738,480		3.3
	20.01-55.00		18,448		0.5		-		-		-		-
			4,557,927		5.5		10,651,097		7.8		11,459,697		7.5

The fair value of equity instruments granted to employees through December 31, 2018 has been determined using the Black-Scholes option-pricing model. These values are based on the following assumptions as of the applicable grant dates:

	2016			2017			2018
Expected dividend yield		0	%		0	%		0	%
Expected volatility		66	%		63	%		61	%
Risk-free interest rate		2	%		2	%		3	%
Expected life of options (in years)		6			6			6

Stock options to consultants

From inception through December 31, 2015, the Company issued to consultants options for the purchase of 81,523 ordinary shares at a weighted average exercise price of NIS 20.69 per share.

In 2016, the Company issued additional options to consultants for the purchase of 150,000 ordinary shares at a weighted average price of NIS 4.55 per share

In 2017, the Company issued additional options to consultants for the purchase of 105,000 ordinary shares at a weighted average price of NIS 4.056 per share

In 2018, the Company issued additional options to consultants for the purchase of 35,000 ordinary shares at a weighted average price of NIS 3.48 per share

The options to consultants generally vest over four years and may be exercised for periods of between five and ten years. As of December 31, 2018, 300,000 options to consultants were outstanding with a weighted average exercise price of NIS 4.42 per share and a weighted average contractual life of 7.80 years.

Company management estimates the fair value of the options granted to consultants based on the value of services received over the vesting period of the applicable options. The value of such services (primarily in respect of clinical advisory services) is estimated based on the additional cash compensation the Company would need to pay if such options were not granted. The value of services recorded in each of the years 2016, 2017 and 2018 was not material.

TAXES ON INCOME

12 Months Ended

Dec. 31, 2018

Disclosure of taxes on income [Abstract]

TAXES ON INCOME

NOTE 12 – TAXES ON INCOME

Corporate taxation in Israel

The income of BioLineRx is taxed at the standard Israeli corporate tax rate, which was 25% in 2016, 24% in 2017 and 23% for 2018 and thereafter.

As the Company has not created any deferred tax assets or liabilities (see Note 2, paragraph l), these differences have no effect on the Company’s financial statements.

Approved enterprise benefits

In May 2012, the Israeli Tax Authority (“ITA”) approved BioLineRx’s eligibility for tax benefits as a “Benefited Enterprise” under the Law for the Encouragement of Capital Investments, 5719-1959, as amended (the “Investments Law”), with respect to certain development programs (the “Eligible Projects”).

Subject to compliance with the applicable requirements, the portion of income eligible for benefits under the Benefited Enterprise regime will be entitled to a tax exemption for a period of two years, followed by five years at the Benefited Enterprise tax rate of 25%, commencing in the first year in which BioLineRx generates taxable income after setting off losses for Israeli tax purposes from prior years (see c. below). The seven-year period may not extend beyond 12 years from the beginning of the Benefited Enterprise’s election year. BioLineRx received Benefited Enterprise status with respect to Eligible Projects in the 2009 and 2012 tax years, so depending on when the Benefited Enterprise programs begin to generate taxable income, the benefits period could continue through 2023. However, any distribution of dividends derived from exempt income sourced in the Benefited Enterprise programs will be subject to a “claw back” of corporate tax at a rate no greater than 25%. In addition, dividends distributed by a publicly traded Israeli company to non-Israeli residents or Israeli individuals are generally subject to withholding tax of 25%. Under an applicable tax treaty, the withholding tax might be lower.

BioLineRx has the option to transition to a “Preferred Enterprise” regime under the Investments Law. Upon an irrevocable election made by a company, a uniform corporate tax rate will apply to all qualifying industrial income of such company, as opposed to the previous incentives under the Investments Law, which were limited to income from Benefited Enterprises during the benefits period. Under the Investments Law, when the election is made, the uniform tax rate for 2018 would be 16% for BioLineRx’s location in Israel. Preferred Enterprise profits are freely distributable as dividends, subject to a 20% withholding tax, or lower under an applicable tax treaty.

In addition, the ITA approved BioLineRx’s operations as an “Industrial Enterprise” under the Investments Law in 2012, meaning that BioLineRx is eligible for accelerated depreciation with respect to certain tangible assets belonging to its Benefited Enterprise. Should BioLineRx not meet the requirements for maintaining these benefits, they may be reduced or cancelled and, among other things, income deriving from the Eligible Projects would be subject to Israeli corporate tax at the standard rates.

Tax loss carryforwards

As of December 31, 2018, the tax loss carryforwards of BioLineRx were approximately $210 million. The tax loss carryforwards have no expiration date.

The Company has not created deferred tax assets in respect of these tax loss carryforwards. See Note 2, paragraph 1.

Tax assessments

In accordance with Israeli tax regulations, the tax returns filed by BioLineRx through the 2013 tax year are considered final.

Theoretical taxes

As described in Note 2, paragraph 1, the Company has not recognized any deferred tax assets in the financial statements, as it does not expect to generate taxable income in the foreseeable future. The reported tax on the Company’s income before taxes differs from the theoretical amount that would arise using the weighted average tax rate applicable to income of the consolidated entities as follows:

	Year ended December 31,
	2016						2017						2018
				USD in						USD in						USD in
				thousands						thousands						thousands
Loss before taxes		25.0	%		(15,841	)		24.0	%		(24,352	)		23.0	%		(22,962	)

Theoretical tax benefit					(3,960	)					(5,962	)					(5,281	)
Disallowed deductions (tax exempt income):
Loss (gain) on adjustment of warrants to fair value					(52	)					30						(401	)
Share-based compensation					269						369						581
Other					15						21						10
Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created					3,728						5,542						5,091
Taxes on income for the reported year					-						-						-

LOSS PER SHARE

12 Months Ended

Dec. 31, 2018

Earnings per share [abstract]

LOSS PER SHARE

NOTE 13 – LOSS PER SHARE

The following table contains the data used in the computation of the basic loss per share:

	Year ended December 31,
	2016			2017			2018
	In USD thousands
Loss attributed to ordinary shares		(15,841	)		(24,352	)		(22,962	)
Number of shares used in basic calculation (in thousands)		56,145			89,971			108,596

	in USD
Basic and diluted loss per ordinary share		(0.28	)		(0.27	)		(0.21	)

COMMITMENTS AND CONTINGENT LIABILITIES

12 Months Ended

Dec. 31, 2018

Disclosure of commitments and contingent liabilities [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 14 – COMMITMENTS AND CONTINGENT LIABILITIES

Commitments

Obligation to pay royalties to the State of Israel

The Company is required to pay royalties to the State of Israel (represented by the Israel Innovation Authority, or IIA), computed on the basis of proceeds from the sale or license of products whose development was supported by grants from the predecessor of the IIA, the Office of the Chief Scientist. This obligation relates solely to financial participation in the development of products by the Company.

In accordance with the terms of grants provided by the IIA, the State is entitled to royalties on the sale or license of any product whose development was supported with State participation. These royalties are generally 3% in the first three years from initial repayment, 4% of sales in the three subsequent years and 5% of sales in the seventh year until repayment of 100% of the grants (linked to the dollar) received by the Company, plus annual interest at the LIBOR rate. Under certain circumstances, the royalty rate is calculated according to a formula based on the ratio of participation by the IIA in the project to the total project costs incurred by the Company

In connection with the in-licensing of BL-8040 from Biokine Therapeutics Ltd. (“Biokine”), and as a condition to IIA consent to the transaction, the Company agreed to abide by any obligations resulting from funds previously received by Biokine from the IIA. The contingent liability to the IIA assumed by the Company relating to this transaction amounts to approximately $3.2 million as of December 31, 2018. The Company has a full right of offset for amounts payable to the IIA from payments due to Biokine in the future. Therefore, in the opinion of management, the likelihood of any future Company payment obligation to the IIA with regard to this matter is remote.

Licensing agreements

From time to time, the Company enters into in-licensing agreements with academic institutions, research institutions and companies (the “licensors”) in connection with the development of therapeutic compounds. Pursuant to these licensing agreements, the Company generally obtains the rights for one or more therapeutic compounds in pre-clinical and early-clinical stages of development, in order to continue development of the compounds through more advanced stages of development and, subsequently, to manufacture, distribute and market the drugs or to out-license the development, manufacturing and commercialization rights to third parties. Such development activities are carried out by either the Company and/or by companies or institutions to which the Company has entered into an out-license agreement, subject to certain restrictions stipulated in the various agreements.

The licenses that have been granted to the Company are broad and comprehensive, and generally include various provisions and usage rights as follows: (i) territorial scope of the license (global); (ii) term of the license (unrestricted but not shorter than the life of the patent); and (iii) development of the therapeutic compound (allowing the Company to perform all development activities on its own, or by outsourcing under Company supervision, as well as out-licensing development under the license to other companies, subject to the provisions of the licensing agreements).

According to the provisions of the licensing agreements, the intellectual property rights in the development of any licensed technology, through the date the applicable license agreement is effective, remain with the licensor, while the rights in products and/or other deliverables developed by the Company after the license is granted belong to the Company. In cases where the licensor has a claim to an invention that was jointly developed with the Company, the licensor also co-owns the related intellectual property. In any event, the scope of the license also covers these intellectual property rights.

In addition, the Company generally undertakes in the licensing agreements to protect registered patents resulting from developments under the various licenses, to promote the registration of patents covering new developments in cooperation with the licensor, and to bear responsibility for all related costs. Pursuant to the various agreements, the Company generally works to register the various patents on a broad basis worldwide, and if the Company decides not to initiate or continue a patent registration proceeding in a given country, the Company is required to notify the applicable licensor to this effect and the licensor is entitled to take action for registration of the patent in such country.

The consideration paid pursuant to the licensing agreements generally includes several components that may be payable over the license period and that relate, inter alia, to the progress made in research and development activities, as well as commercial success, as follows: (a) one-time, up-front payment and/or periodic payments; (b) payments through the early stages of development (i.e., through the end of phase 2); (c) payments upon the achievement of milestones necessary for advancing to phase 3; (d) payments from the end of a successful phase 3 trial through approval of the therapeutic compound; and e) royalties on sales of the final product resulting from development under the license or including any component thereof, ranging between 3%-5% of the Company’s net sales of the product, although in specific instances the royalty rate has been higher or lower than this range. In instances where the Company has out-licensed the product for further development, the Company pays a percentage of the net consideration received from the licensee (“Sublicense Receipts”) to the upstream licensor that generally range from 20% to 29.5% of such consideration, although in specific instances the percentage paid has been higher or lower than this range. These Sublicense Receipts generally take the place of most or all of the milestone and royalty payments set forth in (b) through (e) above.

The license agreements may be cancelled by the licensor only in specific circumstances, generally upon the occurrence of one of the following events: (a) the Company’s failure to meet certain milestones stipulated in the applicable license agreement and appended timetables; (b) default, insolvency, receivership, liquidation, etc. of the Company that is not imposed and/or lifted within the timeframe stipulated in the license agreement; and (c) fundamental breach of the license agreement that is not corrected within the stipulated timeframe. The Company may generally cancel a license agreement with prior notice of 30 to 90 days, due to unsuccessful development or any other cause.

The Company has undertaken to indemnify certain licensors, their employees, officers, representatives or anyone acting on their behalf for any damage and/or expense that they may incur in connection with the Company’s use of a license granted to it, all in accordance with the terms stipulated in the applicable license agreements.

Some of the license agreements are accompanied by consulting, support and cooperation agreements, pursuant to which the Company is committed to pay the various licensers a fixed monthly amount over the period stipulated in the agreement for their assistance in the continued research and development under the license.

Purchase orders

The Company’s outstanding open purchase order commitments as of December 31, 2018 amounted to $13.3 million.

Lease agreements

The Company’s leases its premises under an operating lease agreement entered into in August 2014. Payments under the lease commenced in June 2015 and will expire in June 2020. The monthly lease fee is approximately $28,000 (including maintenance fees and parking). The Company has the option to extend the lease for 3 additional lease periods totaling up to an additional 10 years, each option at a 5% increase to the preceding lease payment amount. As of December 31, 2018, minimum future rental payments (without considering the aforementioned extension periods) under the lease were $340,000 and $177,000 for 2019 and 2020, respectively.

See Note 14b regarding a guarantee provided to secure the Company’s liability under the lease agreement.

The Company has entered into operating lease agreements in connection with a number of vehicles. The lease periods are generally for three years. The annual lease fees, linked to the CPI, are approximately $241,000. To secure the terms of the lease agreements, the Company has made certain prepayments to the leasing companies, representing approximately two months of lease payments. These amounts have been recorded as prepaid expenses. See also Note 16b.

Contingent liabilities

To secure the Company’s lease obligation on its premises, the Company has provided a bank guarantee in the amount of approximately $100,000 for the benefit of the lessor, which remains outstanding as of December 31, 2018. See also Note 10a regarding equipment pledged as collateral to secure a bank loan.

TRANSACTIONS AND BALANCES WITH RELATED PARTIES

12 Months Ended

Dec. 31, 2018

Disclosure of transactions between related parties [abstract]

TRANSACTIONS AND BALANCES WITH RELATED PARTIES

NOTE 15 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES

Transactions with related parties

Expenses:

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Benefits to related parties:
Compensation and benefits to senior management, including benefit component of equity instrument grants		1,912		2,183		2,680
Number of individuals to which this benefit related		6		6		6
Compensation and benefits to directors, including benefit component of equity instrument grants		316		356		307
Number of individuals to which this benefit related		7		7		7

Key management compensation

Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below.

	Year ended December 31,
	2016	2017	2018
	In USD thousands
Salaries and other short-term employee benefits	1,609	1,808	1,669
Post-employment benefits	129	136	137
Other long-term benefits	30	34	35
Share-based compensation	460	561	1,146
	2,228	2,539	2,987

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

12 Months Ended

Dec. 31, 2018

Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

NOTE 16 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION

Other receivables

	December 31,
	2017		2018
	In USD thousands
Government institutions		446		1,337
Other		140		2
		586		1,339

Long-term prepaid expenses

The prepaid expenses relate to operating lease agreements in respect of the vehicles leased by the Company.

Accounts payable and accruals

	December 31,
	2017		2018
	In USD thousands
1) Trade:
Accounts payable:
Overseas		4,350		3,273
In Israel		1,166		1,220
		5,516		4,493
2) Other:
Accrued expenses		620		792
Accrual for vacation and recreation pay		215		287
Payroll and related expenses		259		270
Other		19		14
		1,113		1,363

The carrying amounts of accounts payable and accruals approximate their fair value, as the effect of discounting is not material.

Research and development expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Research and development services		5,501		12,123		11,609
Payroll and related expenses		3,475		5,097		5,704
Lab, occupancy and telephone		769		920		993
Professional fees		678		662		688
Depreciation and amortization		452		452		424
Other		302		256		390
		11,177		19,510		19,808

Sales and marketing expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Payroll and related expenses		659		817		973
Marketing		600		797		291
Overseas travel		93		79		98
		1,352		1,693		1,362

General and administrative expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Payroll and related expenses		2,172		2,060		2,510
Professional fees		1,144		1,298		1,142
Insurance		154		210		221
Depreciation		30		29		27
Other		484		440		535
		3,984		4,037		4,435

Non-operating income (expenses), net

	Year ended December 31,
	2016		2017			2018
	In USD thousands
Issuance costs		-		(133	)		(90	)
Changes in fair value of warrants		207		(127	)		1,743
Gain from realization of long-term investment		-		-			500
Other		7		-			244
		214		(260	)		2,397

Financial income

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Interest income and exchange differences		469		824		719
Gain on foreign currency hedging		11		345		-
		480		1,169		719

Financial expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Interest expense and exchange differences		8		-		452
Bank commissions		14		21		21
		22		21		473

AGALIMMUNE ACQUISITION	12 Months Ended
AGALIMMUNE ACQUISITION	Dec. 31, 2018
Disclosure of Agalimmune Acquisition [Abstract]
AGALIMMUNE ACQUISITION	NOTE 17 – AGALIMMUNE ACQUISITION In March 2017, the Company acquired substantially all the outstanding shares of Agalimmune Ltd. for initial consideration of approximately $6.0 million, of which $3.0 million was in cash and the remainder in the Company’s ADSs. The acquisition expanded the Company’s pipeline to include Agalimmune’s primary asset, AGI-134, a novel immuno-oncology agent for various cancer indications at the near-clinical stage of development. Due in part to the early stage of development of AGI-134 and other elements evaluated by the Company’s management as required by IFRS, the acquisition has been accounted for in the Company’s financial statements as an asset transaction. Total costs associated with bringing the asset into the Company’s pipeline include additional expenses of approximately $0.7 million, resulting in a total increase in intangibles reflected in the Company’s financial statements of approximately $6.7 million as of December 31, 2017. Additional consideration may be due to Agalimmune shareholders based on certain development and commercial milestones, including future sales of Agalimmune products. In addition, the selling shareholders of Agalimmune have certain reversionary rights in the event of a breach of the transaction agreement and certain other limited triggering events.

AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN	12 Months Ended
AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN	Dec. 31, 2018
Disclosure of amendment to license [Abstract]
AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN	NOTE 18 – AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN In October 2018, the Company amended its license agreement with Biokine Therapeutics Ltd. (“Biokine”), originally entered into in September 2012, relating to the in-licensing rights to BL-8040. The amendment reduces the payment owed by the Company to Biokine on sublicense receipts (as defined in the license agreement) from 40% to 20% of sublicense receipts in exchange for: (i) a cash payment from the Company to Biokine of $10 million; (ii) the issuance of 4,980,080 ADSs with a value of $5 million and (iii) the payment of certain future milestone payments, up to an aggregate of $5 million in total, as specified in the amendment. Additionally, in certain limited instances, if the Company enters into a sublicense (as defined in the license agreement) within a defined period, the Company will pay Biokine an additional 10% of any upfront sublicense receipts received by the Company as a result of such sublicense. The $10 million payment referred to above was financed in full via the receipt of a $10 million loan from Kreos Capital V (Expert Fund) L.P. (“Kreos Capital”). As security for the loan, Kreos Capital received a first-priority, secured interest in all Company assets, including intellectual property. The loan has a 12-month, interest-only period, followed by a 36-month repayment period. Borrowings under the loan will bear interest at a fixed rate of 9.5% per annum. In connection with providing the loan, Kreos Capital received a warrant to purchase 957,549 ADSs at an exercise price of $0.94 per ADS. The warrant is exercisable for a period of ten years from the date of issuance. The fair value of the warrant at the date of issuance, computed using the Black and Scholes option pricing model, amounted to $861,000. The fair value was computed based on the then current price of an ADS, a risk-free interest rate of 3.05% and an average standard deviation of 69.1%. The fair value of the warrants as of December 31, 2018 was based on the then current price of an ADS, a risk-free interest rate of 2.69% and an average standard deviation of 68.7%. The change in fair value for the year ended December 31, 2018 of $593,000 has been recorded as non-operating income (expense). The warrant issued has been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The total net proceeds from Kreos Capital were initially allocated to the warrant based on its fair value, with the remainder of the net proceeds allocated to the loan. The loan is treated as a liability at amortized cost

EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	12 Months Ended
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	Dec. 31, 2018
Disclosure of event subsequent to the balance sheet date [Abstract]
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 19 – EVENT SUBSEQUENT TO THE BALANCE SHEET DATE In February 2019, BioLineRx completed an underwritten public offering of 28,000,000 of its ADSs and warrants to purchase 28,000,000 ADSs, at a public offering price of $0.55 per ADS and accompanying warrant. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $0.75 per ADS. The offering raised a total of $15.4 million, with net proceeds of approximately $14.1 million, after deducting fees and expenses.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2018

Disclosure of significant accounting policies [Abstract]

Basis of presentation

The consolidated financial statements have been prepared on the basis of historical cost, subject to adjustment of financial assets and liabilities to their fair value through profit or loss.

The Company classifies its expenses on the statement of comprehensive loss based on the operating characteristics of such expenses.

Principles of consolidation

Functional and reporting currency

Cash equivalents and short-term bank deposits

Property and equipment

	%
Computers and communications equipment		20-33
Office furniture and equipment		6-15
Laboratory equipment		15-20

Leasehold improvements are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the improvements.

Intangible assets

Intellectual property

Computer software

Impairment of non-financial assets

Financial assets

Effective January 1, 2018, the Company adopted IFRS 9 “Financial Instruments.”

Classification

Financial assets at amortized cost

The Company’s financial assets at amortized cost are included in other receivables and bank deposits in the consolidated statements of financial position.

Financial assets at fair value through profit or loss

Recognition and measurement

Impairment

Warrants

Share capital

The Company’s ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of new shares are shown in equity as a deduction from the issuance proceeds.

Trade payables

Deferred taxes

Revenue from contract with customers

Effective January 1, 2018, the Company adopted IFRS 15, “Revenue from Contracts with Customers.”

IFRS 15 introduces a five-step model for recognizing revenue from contracts with customers, as follows:

identify the contract with a customer;

identify the performance obligations in the contract;

determine the transaction price;

allocate the transaction price to the performance obligations in the contract; and

recognize revenue when (or as) the entity satisfies a performance obligation.

Research and development expenses

Research expenses are charged to profit or loss as incurred.

An intangible asset arising from development (or from the development phase of an internal project) is recognized if all of the following conditions are fulfilled:

technological feasibility exists for completing development of the intangible asset so that it will be available for use or sale.

it is management’s intention to complete development of the intangible asset for use or sale.

the Company has the ability to use or sell the intangible asset.

adequate technical, financial and other resources are available to complete development of the intangible asset, as well as the use or sale thereof.

the Company has the ability to reliably measure the expenditure attributable to the intangible asset during its development.

Employee benefits

Pension and severance pay obligations

The amounts recorded as an employee benefit expense in respect of pension and severance pay obligations for the years 2016, 2017 and 2018 were $523,000, $563,000 and $618,000 respectively.

Vacation and recreation pay

Share-based payments

including any market performance conditions (for example, the Company’s share price); and

Loss per share

Basic

The basic loss per share is calculated by dividing the loss attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the year.

Diluted

Standards and interpretations to existing standards that are not yet in effect and have not been early adopted by the Company

International Financial Reporting Standard No. 16 “Leases” (“IFRS 16”)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of significant accounting policies [Abstract]

Schedule of Depreciation Rates

	%
Computers and communications equipment		20-33
Office furniture and equipment		6-15
Laboratory equipment		15-20

FINANCIAL RISK MANAGEMENT (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about financial instruments [abstract]

Schedule of Sensitivity Analysis

The effect of fluctuations in various exchange rates on the Company’s income and equity is as follows:

	December 31, 2018
	Income (loss)						Value on			Income (loss)
Sensitive instrument	10% increase			5% increase			balance sheet			5% decrease			10% decrease
	in USD thousands
NIS-linked balances:
Cash and cash equivalents		(64	)		(33	)		699			37			78
Other receivables		(45	)		(23	)		491			26			55
Trade payables		73			38			(807	)		(42	)		(90	)
Other payables		57			30			(632	)		(33	)		(70	)
Total NIS-linked balances		21			12			(249	)		(12	)		(27	)
Euro-linked trade payables		(177	)		(93	)		(453	)		102			216
Total		(156	)		(81	)		(702	)		90			189

The Company also maintains cash and cash equivalent balances in other currencies in amounts that are not material.

	December 31, 2017
	Income (loss)						Value on			Income (loss)
Sensitive instrument	10% increase			5% increase			balance sheet			5% decrease			10% decrease
	in USD thousands
NIS-linked balances:
Cash and cash equivalents		(216	)		(113	)		2,376			125			264
Other receivables		(30	)		(15	)		325			17			36
Trade payables		69			36			(764	)		(40	)		(85	)
Other payables		69			36			(756	)		(40	)		(84	)
Total NIS-linked balances		(108	)		(56	)		1,181			62			131
Euro-linked trade payables		(94	)		(49	)		(1,031	)		(54	)		(115	)
Total		(202	)		(105	)		150			8			16

Schedule of Concentration of Currency Risk

Set forth below is certain data regarding dollar exchange rates:

	Exchange rate of NIS per $1		Exchange rate of Euro per $1
As of December 31:
2016		3.845		0.951
2017		3.467		0.835
2018		3.748		0.873

Percentage increase (decrease) in:
2017		(9.8%)		(12.2%)
2018		8.1%		4.6%

Schedule of Linkage of Monetary Items

Set forth below is information on the linkage of monetary items:

	December 31, 2017							December 31, 2018
	Dollar		NIS		Other currencies			Dollar		NIS			GBP and other
	USD in thousands							USD in thousands
Assets:
Current assets:
Cash and cash equivalents		2,623		2,376		111			2,274		699			431
Short term bank deposits		44,373		-		-			26,747		-			-
Other receivables		117		325		144			-		491			848
Total assets		47,113		2,701		255			29,021		1,190			1,279
Liabilities:
Current liabilities:
Current maturities of bank loan		93		-		-			895		-			-
Accounts payable and accruals:
Trade		3,018		764		1,734			2,396		807			1,290
Other		99		756		258			708		632			23
Non-current liabilities
Long-term bank loan, net of current maturities		157		-		-			7,838		-			-
		3,367		1,520		1,992			11,837		1,439			1,313
Net asset value		43,746		1,181		(1,737	)		17,184		(249	)		(34	)

Schedule of Credit Risk

The Company considers its maximum exposure to credit risk to be as follows:

	December 31,
	2017		2018
	in USD thousands
Assets:
Cash and cash equivalents		5,110		3,404
Short-term bank deposits		44,373		26,747
Other receivables		586		1,339
Total		50,069		31,490

CASH AND CASH EQUIVALENTS (Tables)

12 Months Ended

Dec. 31, 2018

Cash and cash equivalents [abstract]

Schedule of Cash And Cash Equivalents

	December 31,
	2017		2018
	in USD thousands

Cash on hand and in bank		3,960		2,329
Short-term bank deposits		1,150		1,075
		5,110		3,404

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about property, plant and equipment [abstract]

Schedule of Composition of Property and Equipment and Related Accumulated Depreciation

Set forth below are the composition of property and equipment and the related accumulated depreciation, grouped by major classifications, as well as the changes therein for the respective years:

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2015		2016
	In USD thousands								In USD thousands								In USD thousands
Composition in 2016
Office furniture and equipment		198		-		-		198		13		12		-		25		185		173
Computers and communications equipment		446		43		-		489		355		53		-		408		91		81
Laboratory equipment		1,194		104		-		1,298		482		188		-		670		712		628
Leasehold improvements		2,025		3		-		2,028		104		201		-		305		1,921		1,723
		3,863		150		-		4,013		954		454		-		1,408		2,909		2,605

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2016		2017
	In USD thousands								In USD thousands								In USD thousands
Composition in 2017
Office furniture and equipment		198		2		-		200		25		35		-		60		173		140
Computers and communications equipment		489		266		-		755		408		30		-		438		81		317
Laboratory equipment		1,298		70		-		1,368		670		159		-		829		628		539
Leasehold improvements		2,028		-		-		2,028		305		214		-		519		1,723		1,509
		4,013		338		-		4,351		1,408		438		-		1,846		2,605		2,505

	Cost								Accumulated depreciation
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2017		2018
	In USD thousands								In USD thousands								In USD thousands
Composition in 2018
Office furniture and equipment		200		-		-		200		60		22		-		82		140		118
Computers and communications equipment		755		9		-		764		438		60		-		498		317		266
Laboratory equipment		1,368		164		-		1,532		829		153		-		982		539		550
Leasehold improvements		2,028		-		-		2,028		519		216		-		735		1,509		1,293
		4,351		173		-		4,524		1,846		451		-		2,297		2,505		2,227

INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about intangible assets [abstract]

Schedule of Intangible Assets

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2015		2016
	In USD thousands								In USD thousands								In USD thousands
Composition in 2016
Intellectual property		193		-		-		193		96		-		-		96		97		97
Computer software		328		57		-		385		273		28		-		301		55		84
		521		57		-		578		369		28		-		397		152		181

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2016		2017
	In USD thousands								In USD thousands								In USD thousands
Composition in 2017
Intellectual property		193		6,703		-		6,896		96		-		-		96		97		6,800
Computer software		385		182		-		567		301		43		-		344		84		223
		578		6,885		-		7,463		397		43		-		440		181		7,023

	Cost								Accumulated depreciation and impairment
	Balance at		Additions		Deletions		Balance at		Balance at		Additions		Deletions		Balance at		Net book value
	beginning		during		during		end of		beginning		during		during		end of		December 31,
	of year		year		year		year		of year		year		year		year		2017		2018
	In USD thousands								In USD thousands								In USD thousands
Composition in 2018
Intellectual property		6,896		15,000		-		21,896		96		-		-		96		6,800		21,800
Computer software		567		43		-		610		344		94		-		438		223		172
		7,463		15,043		-		22,506		440		94		-		534		7,023		21,972

LONG-TERM LOANS (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about borrowings [abstract]

Schedule of Composition of Long-Term Bank Loan

	December 31,
	2017			2018
	In USD thousands

Bank loan (1)		250			156
Loan from Kreos Capital (Note 18)		-			8,577
		250			8,733
Less current maturities:
Bank loan		(93	)		(93	)
Loan from Kreos Capital		-			(802	)
Total current maturities		(93	)		(895	)
Total long-term loans		157			7,838

(1)

Schedule of Future Repayments of Long-Term Bank Loan

Future repayments of the long-term loans indicated above (other than current maturities) in the years subsequent to the balance sheet date are as follows:

	Bank loan		Loan from Kreos Capital		Total
	In USD thousands
2020		63		2,402		2,465
2021		-		2,892		2,892
2022		-		2,481		2,481
		63		7,775		7,838

EQUITY (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of classes of share capital [abstract]

Schedule of Share Capital

As of December 31, 2017, and 2018 the Company’s share capital is composed of ordinary shares, as follows:

	Number of Ordinary Shares
	December 31,
	2017		2018

Authorized share capital		250,000,000		250,000,000

Issued and paid-up share capital		105,063,437		114,933,144

	In USD and NIS
	December 31,
	2017		2018

Authorized share capital (in NIS)		25,000,000		25,000,000

Issued and paid-up share capital (in NIS)		10,506,344		11,493,314

Issued and paid-up share capital (in USD)		2,836,139		3,109,746

Schedule of Amounts Outstanding Under Employee Share Incentive Plan

The following table contains additional information concerning equity instruments granted to employees and directors under the existing share incentive plans.

	Year ended December 31,
	2016					2017					2018
	Number of options			Weighted average exercise price (in NIS)		Number of options			Weighted average exercise price (in NIS)		Number of options			Weighted average exercise price (in NIS)
Outstanding at beginning of year		3,500,262			8.7		4,557,927			6.5		10,651,097			4.4
Granted		2,505,684			3.8		7,292,560			3.5		2,853,080			2.8
Forfeited and expired		(1,435,990	)		7.2		(1,164,961	)		6.5		(1,649,090	)		4.0
Exercised		(12,029	)		0.4		(34,429	)		0.2		(395,390	)		0.4
Outstanding at end of year*		4,557,927			6.5		10,651,097			4.4		11,459,697			4.2
Exercisable at end of year		1,786,209			9.4		2,356,948			7.6		4,489,816			5.9

Schedule of Options Outstanding by Exercise Price Range

		Year ended December 31,
		2016				2017				2018
Range of exercise prices (in NIS)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)		Number of options outstanding		Weighted average remaining contractual life (in yrs.)
Up to 5.00			1,979,244		8.2		8,642,472		8.2		9,631,342		8.2
	5.01-10.00		1,522,800		4.3		1,213,225		5.9		1,089,875		4.3
	10.01-20.00		1,037,436		2.7		795,400		4.7		738,480		3.3
	20.01-55.00		18,448		0.5		-		-		-		-
			4,557,927		5.5		10,651,097		7.8		11,459,697		7.5

Schedule of Assumptions Used to Value Options

	2016			2017			2018
Expected dividend yield		0	%		0	%		0	%
Expected volatility		66	%		63	%		61	%
Risk-free interest rate		2	%		2	%		3	%
Expected life of options (in years)		6			6			6

TAXES ON INCOME (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of taxes on income [Abstract]

Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income

	Year ended December 31,
	2016						2017						2018
				USD in						USD in						USD in
				thousands						thousands						thousands
Loss before taxes		25.0	%		(15,841	)		24.0	%		(24,352	)		23.0	%		(22,962	)

Theoretical tax benefit					(3,960	)					(5,962	)					(5,281	)
Disallowed deductions (tax exempt income):
Loss (gain) on adjustment of warrants to fair value					(52	)					30						(401	)
Share-based compensation					269						369						581
Other					15						21						10
Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created					3,728						5,542						5,091
Taxes on income for the reported year					-						-						-

LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2018

Earnings per share [abstract]

Schedule of Basic Loss Per Share

The following table contains the data used in the computation of the basic loss per share:

	Year ended December 31,
	2016			2017			2018
	In USD thousands
Loss attributed to ordinary shares		(15,841	)		(24,352	)		(22,962	)
Number of shares used in basic calculation (in thousands)		56,145			89,971			108,596

	in USD
Basic and diluted loss per ordinary share		(0.28	)		(0.27	)		(0.21	)

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of transactions between related parties [abstract]

Schedule of Transactions With Related Parties

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Benefits to related parties:
Compensation and benefits to senior management, including benefit component of equity instrument grants		1,912		2,183		2,680
Number of individuals to which this benefit related		6		6		6
Compensation and benefits to directors, including benefit component of equity instrument grants		316		356		307
Number of individuals to which this benefit related		7		7		7

Schedule of Key Management Compensation

Key management includes directors and executive officers. The compensation paid or payable to key management for services during each of the years indicated is presented below.

	Year ended December 31,
	2016	2017	2018
	In USD thousands
Salaries and other short-term employee benefits	1,609	1,808	1,669
Post-employment benefits	129	136	137
Other long-term benefits	30	34	35
Share-based compensation	460	561	1,146
	2,228	2,539	2,987

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2018

Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses

Schedule of Other Receivables

	December 31,
	2017		2018
	In USD thousands
Government institutions		446		1,337
Other		140		2
		586		1,339

Schedule of Accounts Payable and Accruals

	December 31,
	2017		2018
	In USD thousands
1) Trade:
Accounts payable:
Overseas		4,350		3,273
In Israel		1,166		1,220
		5,516		4,493
2) Other:
Accrued expenses		620		792
Accrual for vacation and recreation pay		215		287
Payroll and related expenses		259		270
Other		19		14
		1,113		1,363

Schedule of Income and Expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Research and development services		5,501		12,123		11,609
Payroll and related expenses		3,475		5,097		5,704
Lab, occupancy and telephone		769		920		993
Professional fees		678		662		688
Depreciation and amortization		452		452		424
Other		302		256		390
		11,177		19,510		19,808

Sales and marketing expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Payroll and related expenses		659		817		973
Marketing		600		797		291
Overseas travel		93		79		98
		1,352		1,693		1,362

General and administrative expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Payroll and related expenses		2,172		2,060		2,510
Professional fees		1,144		1,298		1,142
Insurance		154		210		221
Depreciation		30		29		27
Other		484		440		535
		3,984		4,037		4,435

Non-operating income (expenses), net

	Year ended December 31,
	2016		2017			2018
	In USD thousands
Issuance costs		-		(133	)		(90	)
Changes in fair value of warrants		207		(127	)		1,743
Gain from realization of long-term investment		-		-			500
Other		7		-			244
		214		(260	)		2,397

Financial income

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Interest income and exchange differences		469		824		719
Gain on foreign currency hedging		11		345		-
		480		1,169		719

Financial expenses

	Year ended December 31,
	2016		2017		2018
	In USD thousands
Interest expense and exchange differences		8		-		452
Bank commissions		14		21		21
		22		21		473

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about intangible assets [line items]
Employee benefit expense		$ 618	$ 563	$ 523
Increase in Operating cash flows		(24,192)	(20,547)	(14,513)
Increase in Financing cash flows		$ 13,097	$ 38,680	$ 2,090
IFRS 16 [Member]
Disclosure of detailed information about intangible assets [line items]
Right-of-use assets	$ 1,900
Lease liabilities	1,900
Increase in Operating cash flows	300
Increase in Financing cash flows	$ 300
Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives of intangible assets (In years)		3-5 years

SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates) (Details) - Net book value [Member]	12 Months Ended
	Dec. 31, 2018
Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	20%-33%
Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	6%-15%
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation rates (in %)	15%-20%

FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Cash and cash equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	$ (64)	$ (216)
5% increase effect on net income (loss) and equity	(33)	(113)
Value on balance sheet	699	2,376
5% decrease effect on net income (loss) and equity	37	125
10% decrease effect on net income (loss) and equity	78	264
Other receivables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(45)	(30)
5% increase effect on net income (loss) and equity	(23)	(15)
Value on balance sheet	491	325
5% decrease effect on net income (loss) and equity	26	17
10% decrease effect on net income (loss) and equity	55	36
Trade payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	73	69
5% increase effect on net income (loss) and equity	38	36
Value on balance sheet	(807)	(764)
5% decrease effect on net income (loss) and equity	(42)	(40)
10% decrease effect on net income (loss) and equity	(90)	(85)
Other payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	57	69
5% increase effect on net income (loss) and equity	30	36
Value on balance sheet	(632)	(756)
5% decrease effect on net income (loss) and equity	(33)	(40)
10% decrease effect on net income (loss) and equity	(70)	(84)
NIS-linked balances [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	21	(108)
5% increase effect on net income (loss) and equity	12	(56)
Value on balance sheet	(249)	1,181
5% decrease effect on net income (loss) and equity	(12)	62
10% decrease effect on net income (loss) and equity	(27)	131
Euro-linked trade payables [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(177)	(94)
5% increase effect on net income (loss) and equity	(93)	(49)
Value on balance sheet	(453)	(1,031)
5% decrease effect on net income (loss) and equity	102	(54)
10% decrease effect on net income (loss) and equity	216	(115)
Total [Member]
Disclosure of detailed information about financial instruments [line items]
10% increase effect on net income (loss) and equity	(156)	(202)
5% increase effect on net income (loss) and equity	(81)	(105)
Value on balance sheet	(702)	150
5% decrease effect on net income (loss) and equity	90	8
10% decrease effect on net income (loss) and equity	$ 189	$ 16

FINANCIAL RISK MANAGEMENT (Schedule of Concentration of Currency Risk) (Details)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
NIS per $1
Disclosure of risk management strategy related to hedge accounting [line items]
Exchange rate per dollar	3.748	3.467	3.845
Percentage increase (decrease) in exchange rate	8.10%	(9.80%)
Euro per $1
Disclosure of risk management strategy related to hedge accounting [line items]
Exchange rate per dollar	0.873	0.835	0.951
Percentage increase (decrease) in exchange rate	4.60%	(12.20%)

FINANCIAL RISK MANAGEMENT (Schedule of Linkage of Monetary Items) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 3,404	$ 5,110	$ 2,469	$ 5,544
Total assets	56,233	60,965
Current liabilities:
Current maturities of bank loan	895	93
Accounts payable and accruals:
Trade	4,493	5,516
Other	14	19
Non-current liabilities
Long-term bank loan, net of current maturities	7,838	157
Total liabilities	14,912	8,084
Dollar [Member]
Current assets:
Cash and cash equivalents	2,274	2,623
Short term bank deposits	26,747	44,373
Other receivables		117
Total assets	29,021	47,113
Current liabilities:
Current maturities of bank loan	895	93
Accounts payable and accruals:
Trade	2,396	3,018
Other	708	99
Non-current liabilities
Long-term bank loan, net of current maturities	7,838	157
Total liabilities	11,837	3,367
Net asset value	17,184	43,746
NIS [Member]
Current assets:
Cash and cash equivalents	699	2,376
Short term bank deposits
Other receivables	491	325
Total assets	1,190	2,701
Current liabilities:
Current maturities of bank loan
Accounts payable and accruals:
Trade	807	764
Other	632	756
Non-current liabilities
Long-term bank loan, net of current maturities
Total liabilities	1,439	1,520
Net asset value	(249)	1,181
GBP and other [Member]
Current assets:
Cash and cash equivalents	431	111
Short term bank deposits
Other receivables	848	144
Total assets	1,279	255
Current liabilities:
Current maturities of bank loan
Accounts payable and accruals:
Trade	1,290	1,734
Other	23	258
Non-current liabilities
Long-term bank loan, net of current maturities
Total liabilities	1,313	1,992
Net asset value	$ (34)	$ (1,737)

FINANCIAL RISK MANAGEMENT (Schedule of Credit Risk) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets:
Cash and cash equivalents	$ 3,404	$ 5,110	$ 2,469	$ 5,544
Total assets	56,233	60,965
Credit risk [member]
Assets:
Cash and cash equivalents	3,404	5,110
Short term bank deposits	26,747	44,373
Other receivables	1,339	586
Total assets	$ 31,490	$ 50,069

CASH AND CASH EQUIVALENTS (Narrative) (Details)	12 Months Ended
CASH AND CASH EQUIVALENTS (Narrative) (Details)	Dec. 31, 2018
Cash and cash equivalents [abstract]
Interest rate on short-term deposits	0.15%

CASH AND CASH EQUIVALENTS (Schedule of Cash And Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and cash equivalents [abstract]
Cash on hand and in bank	$ 2,329	$ 3,960
Short-term bank deposits	1,075	1,150
Cash and cash equivalents	$ 3,404	$ 5,110	$ 2,469	$ 5,544

SHORT-TERM BANK DEPOSITS (Narrative) (Details)	12 Months Ended
SHORT-TERM BANK DEPOSITS (Narrative) (Details)	Dec. 31, 2018
Bottom of range [Member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	1.58%
Top of range [Member]
Disclosure of detailed information about financial instruments [line items]
Interest rate on short-term deposits	3.08%

LONG-TERM INVESTMENT (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
LONG-TERM INVESTMENT (Details) - USD ($) $ in Thousands	Apr. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of joint ventures [line items]
Initial seed capital to joint venture			$ 1,000
Net gain		$ 1,500
I-Bridge Capital [Member]
Disclosure of joint ventures [line items]
Initial seed capital to joint venture				$ 1,000
Cash consideration to joint venture	$ 1,500
Net gain	$ 500

PROPERTY AND EQUIPMENT (Schedule of Composition of Property and Equipment and Related Accumulated Depreciation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	$ 2,505
Balance at end of year	2,227	$ 2,505
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	4,351	4,013	$ 3,863
Additions during year	173	338	150
Deletions during year
Balance at end of year	4,524	4,351	4,013
Cost [Member] \| Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	200	198	198
Additions during year		2
Deletions during year
Balance at end of year	200	200	198
Cost [Member] \| Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	755	489	446
Additions during year	9	266	43
Deletions during year
Balance at end of year	764	755	489
Cost [Member] \| Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	1,368	1,298	1,194
Additions during year	164	70	104
Deletions during year
Balance at end of year	1,532	1,368	1,298
Cost [Member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	2,028	2,028	2,025
Additions during year			3
Deletions during year
Balance at end of year	2,028	2,028	2,028
Accumulated depreciation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	1,846	1,408	954
Additions during year	451	438	454
Deletions during year
Balance at end of year	2,297	1,846	1,408
Accumulated depreciation [member] \| Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	60	25	13
Additions during year	22	35	12
Deletions during year
Balance at end of year	82	60	25
Accumulated depreciation [member] \| Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	438	408	355
Additions during year	60	30	53
Deletions during year
Balance at end of year	498	438	408
Accumulated depreciation [member] \| Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	829	670	482
Additions during year	153	159	188
Deletions during year
Balance at end of year	982	829	670
Accumulated depreciation [member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	519	305	104
Additions during year	216	214	201
Deletions during year
Balance at end of year	735	519	305
Net book value [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	2,505	2,605	2,909
Balance at end of year	2,227	2,505	2,605
Net book value [Member] \| Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	140	173	185
Balance at end of year	118	140	173
Net book value [Member] \| Computers and communications equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	317	81	91
Balance at end of year	266	317	81
Net book value [Member] \| Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	539	628	712
Balance at end of year	550	539	628
Net book value [Member] \| Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	1,509	1,723	1,921
Balance at end of year	$ 1,293	$ 1,509	$ 1,723

INTANGIBLE ASSETS (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	$ 7,023
Balance at end of year	21,972	$ 7,023
Net book value [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	7,023	181	$ 152
Balance at end of year	21,972	7,023	181
Net book value [Member] \| Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	6,800	97	97
Balance at end of year	21,800	6,800	97
Net book value [Member] \| Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	223	84	55
Balance at end of year	172	223	84
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	7,463	578	521
Additions during year	15,043	6,885	57
Deletions during year
Balance at end of year	22,506	7,463	578
Cost [Member] \| Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	6,896	193	193
Additions during year	15,000	6,703
Deletions during year
Balance at end of year	21,896	6,896	193
Cost [Member] \| Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	567	385	328
Additions during year	43	182	57
Deletions during year
Balance at end of year	610	567	385
Accumulated depreciation and impairmentt [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	440	397	369
Additions during year	94	43	28
Deletions during year
Balance at end of year	534	440	397
Accumulated depreciation and impairmentt [Member] \| Intellectual property [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	96	96	96
Additions during year
Deletions during year
Balance at end of year	96	96	96
Accumulated depreciation and impairmentt [Member] \| Computer software [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	344	301	273
Additions during year	94	43	28
Deletions during year
Balance at end of year	$ 438	$ 344	$ 301

LONG-TERM LOANS (Narrative) (Details)	Dec. 31, 2018
Disclosure of detailed information about borrowings [abstract]
Interest rate on long term bank loan	3.75%

LONG-TERM LOANS (Schedule of Composition of Long-Term Loans) (Details) - USD ($)
$ in Thousands

Dec. 31, 2018

Dec. 31, 2017

Disclosure of detailed information about borrowings [line items]

Loan

$ 8,733

$ 250

^[1]

Less current maturities

(895)

(93)

Long-term bank loan, net of current maturities

7,838

157

Bank Loan [Member]

Disclosure of detailed information about borrowings [line items]

Loan

156

250

^[1]

Less current maturities

(93)

Long-term bank loan, net of current maturities

Loan from Kreos Capital [Member]

Disclosure of detailed information about borrowings [line items]

Loan

8,577

^[1]

Less current maturities

(802)

Long-term bank loan, net of current maturities

$ 7,775

[1]	The loan is denominated in dollars and bears interest at an annual rate of 3.75%. The book value of the loan approximates its fair value. The loan is repayable in 60 monthly installments and is collateralized by certain lab equipment.

LONG-TERM LOANS (Schedule of Future Repayments of Long-Term Loans) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about borrowings [line items]
2020	$ 2,465
2021	2,892
2022	2,481
Future repayments of long-term bank loan	7,838	$ 157
Bank Loan [Member]
Disclosure of detailed information about borrowings [line items]
2020	63
2021
2022
Future repayments of long-term bank loan	63
Loan from Kreos Capital [Member]
Disclosure of detailed information about borrowings [line items]
2020	2,402
2021	2,892
2022	2,481
Future repayments of long-term bank loan	$ 7,775

EQUITY (Narrative) (Details)	1 Months Ended				12 Months Ended					63 Months Ended	153 Months Ended
EQUITY (Narrative) (Details)	Jul. 31, 2017 USD ($) $ / shares shares	Apr. 30, 2017 USD ($) $ / shares shares	Mar. 31, 2015 USD ($) $ / shares shares	May 30, 2014 USD ($)	Dec. 31, 2018 USD ($) shares yr $ / shares	Dec. 31, 2018 ILS (₪) shares	Dec. 31, 2017 USD ($) shares yr	Dec. 31, 2016 USD ($) shares yr	Dec. 31, 2013	Dec. 31, 2017 USD ($) shares yr	Dec. 31, 2015 ILS (₪) shares	Mar. 31, 2019 shares	Oct. 31, 2017 USD ($)	Nov. 30, 2014 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maturity date of warrant					February 2017	February 2017
Underwritten public offering \| shares		33,823,529	14,375,000
Public offering price \| $ / shares		$ 0.85	$ 2.00
Proceeds from public offering, gross		$ 28,800,000	$ 28,800,000
Proceeds from public offering, net		$ 26,200,000	$ 26,400,000
Issuance expense					$ 90,000		$ 133,000
Gross proceeds					$ 3,830,000		$ 38,773,000	$ 2,183,000
Ordinary shares, authorized \| shares					250,000,000		250,000,000			250,000,000
Remaining authorized unissued ordinary shares \| shares					1,800,000									14,800,000
Exercise price \| ₪						₪ 0.1
Option outstanding \| shares					11,459,697		10,651,097	4,557,927		10,651,097
Weighted average contractual life \| yr					7.5		7.8	5.5		7.8
Risk-free interest rate (%)					3.00%	3.00%	2.00%	2.00%
Average standard deviation					61.00%	61.00%	63.00%	66.00%
BTIG, LLC [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share purchase agreement, shares \| shares					5,439,203
Net proceeds from transaction					$ 5,100,000
Available balance under the facility					24,900,000
Aggregate offering price													$ 30,000,000
Percentage of commission on sales agreement													3.00%
Warrant [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Change in fair value					$ 1,200,000		$ 100,000
Risk-free interest rate (%)	1.66%				2.47%	2.47%	2.09%
Average standard deviation	57.80%				55.30%	55.30%	56.80%
Direct Placement [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Change in fair value	$ 1,100,000
OrbiMed Advisors LLC [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercisable term of warrant									5 Years
BVF Partners L.P. [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued to purchase warrant \| shares	8,495,575
Gross proceeds	$ 9,600,000
Net proceeds from transaction	$ 9,500,000
BVF Partners L.P. [Member] \| Series A [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued to purchase warrant \| shares	2,973,451
Exercise price of shares issued \| $ / shares	$ 2.00
Exercisable term of warrant	4 Years
BVF Partners L.P. [Member] \| Series B [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares issued to purchase warrant \| shares	2,973,451
Exercise price of shares issued \| $ / shares	$ 4.00
Exercisable term of warrant	4 Years
Lincoln Park Capital Fund [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share purchase agreement				$ 20,000,000
Purchase agreement period				36 months
Share issued as additional commitment fee \| shares					150	150				138,766
Commitment fee					$ 300,000					$ 140,000
Additional commitment fee					$ 500,000
Gross proceeds										$ 7,000,000
Sale of stock \| shares										5,550,603
Consultants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Ordinary shares, issued \| shares					35,000		105,000	150,000		105,000	81,523
Weighted average exercise price					$ 3.48		$ 4.056	$ 4.55			₪ 20.69
Option vested and exercised					The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.	The options to consultants generally vest over four years and may be exercised for periods of between five and ten years.
Option outstanding \| shares					300,000
Weighted average exercise price \| ₪						₪ 4.42
Weighted average contractual life \| yr					7.80
BioLineRx [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Commitment fee					$ 50,000
Additional commitment fee					$ 200,000
Percentage of commission on sales agreement					2.00%
NASDAQ [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Market price of ordinary shares \| $ / shares					$ 0.44
TASE [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Market price of ordinary shares \| $ / shares					$ 1.63
2003 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Ordinary shares, issued \| shares					11,759,697
Remaining authorized unissued ordinary shares \| shares							5,200,000			5,200,000	5,000,000			1,600,000
2003 Plan [Member] \| Additional Shares [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Remaining authorized unissued ordinary shares \| shares												9,000,000
PSU [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Option vested \| shares					285,410	285,410

EQUITY (Schedule of Share Capital) (Details) ₪ in Thousands, $ in Thousands	Dec. 31, 2018 USD ($) shares	Dec. 31, 2018 ILS (₪) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2017 ILS (₪) shares
Number of Ordinary Shares
Authorized share capital \| shares	250,000,000	250,000,000	250,000,000	250,000,000
Issued and paid-up share capital \| shares	114,933,144	114,933,144	105,063,437	105,063,437
Issued and paid-up share capital \| $	$ 3,109,746		$ 2,836,139
NIS [Member]
Number of Ordinary Shares
Authorized share capital \| ₪		₪ 25,000,000		₪ 25,000,000
Issued and paid-up share capital \| ₪		₪ 11,493,314		₪ 10,506,344

EQUITY (Schedule of Amounts Outstanding Under Employee Share Incentive Plan) (Details)

12 Months Ended

Dec. 31, 2018

ILS (₪)

Dec. 31, 2017

ILS (₪)

Dec. 31, 2016

ILS (₪)

Number of options

Outstanding at beginning of year

10,651,097

4,557,927

Outstanding at end of year

11,459,697

10,651,097

4,557,927

Employees and Directors [Member]

Number of options

Outstanding at beginning of year

10,651,097

^[1]

4,557,927

^[1]

3,500,262

Granted

2,853,080

7,292,560

2,505,684

Forfeited and expired

(1,649,090)

(1,164,961)

(1,435,990)

Exercised

(395,390)

(34,429)

(12,029)

Outstanding at end of year

^[1]

11,459,697

10,651,097

4,557,927

Exercisable at end of year

4,489,816

2,356,948

1,786,209

Weighted average exercise price (in NIS)

Outstanding at beginning of year | ₪

₪ 4.4

^[1]

₪ 6.5

^[1]

₪ 8.7

Granted | ₪

2.8

3.5

3.8

Forfeited and expired | ₪

6.5

7.2

Exercised | ₪

0.4

0.2

0.4

Outstanding at end of year | ₪

^[1]

4.2

4.4

6.5

Exercisable at end of year | ₪

₪ 5.9

₪ 7.6

₪ 9.4

[1]	As of the December 31, 2016, 2017 and 2018, includes 222,428, 1,178,128 and 1,163,018 PSUs at an exercise price of 0.10 NIS, for which performance obligations have not been met.

EQUITY (Schedule of Options Outstanding by Exercise Price Range) (Details)	Dec. 31, 2018 shares yr	Dec. 31, 2017 shares yr	Dec. 31, 2016 shares yr
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding \| shares	11,459,697	10,651,097	4,557,927
Weighted average remaining contractual (in Yrs.) \| yr	7.5	7.8	5.5
Up to 5.00 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding \| shares	9,631,342	8,642,472	1,979,244
Weighted average remaining contractual (in Yrs.) \| yr	8.2	8.2	8.2
5.01-10.00 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding \| shares	1,089,875	1,213,225	1,522,800
Weighted average remaining contractual (in Yrs.) \| yr	4.3	5.9	4.3
10.01-20.00 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding \| shares	738,480	795,400	1,037,436
Weighted average remaining contractual (in Yrs.) \| yr	3.3	4.7	2.7
20.01-55.00 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of options outstanding \| shares			18,448
Weighted average remaining contractual (in Yrs.) \| yr			0.5

EQUITY (Schedule of Assumptions Used to Value Options) (Details) - yr	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [abstract]
Expected dividend yield (%)	0.00%	0.00%	0.00%
Expected volatility (%)	61.00%	63.00%	66.00%
Risk-free interest rate (%)	3.00%	2.00%	2.00%
Expected life of options (in years)	6	6	6

TAXES ON INCOME (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of non-adjusting events after reporting period [line items]
Corporate tax rate	23.00%	24.00%	25.00%
Withholding income tax rate	20.00%
Tax loss carryforwards	$ 210
Changes in tax rates or tax laws enacted or announced [Member]
Disclosure of non-adjusting events after reporting period [line items]
Future enacted tax rate	23.00%	24.00%
Uniform tax rate	16.00%
Israel [Member]
Disclosure of non-adjusting events after reporting period [line items]
Corporate tax rate	0.00%	24.00%	25.00%

TAXES ON INCOME (Schedule of Reconciliation of Weighted Average Tax Rate Applicable to Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of taxes on income [Abstract]
Loss before taxes (Percentage)	23.00%	24.00%	25.00%
Loss before taxes	$ (22,962)	$ (24,352)	$ (15,841)
Theoretical tax benefit	(5,281)	(5,962)	(3,960)
Disallowed deductions (tax exempt income):
Loss (gain) on adjustment of warrants to fair value	(401)	30	(52)
Share-based compensation	581	369	269
Other	10	21	15
Increase in taxes for tax losses and timing differences incurred in the reporting year for which deferred taxes were not created	5,091	5,542	3,728
Taxes on income for the reported year

LOSS PER SHARE (Schedule of Basic Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Earnings per share [abstract]
Loss attributed to ordinary shares	$ (22,962)	$ (24,352)	$ (15,841)
Number of shares used in basic calculation	108,595,702	89,970,713	56,144,727
Basic and diluted loss per ordinary share	$ (0.21)	$ (0.27)	$ (0.28)

COMMITMENTS AND CONTINGENT LIABILITIES (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage	100.00%
Contingent liability	$ 3,200
Lease agreement monthly fee	$ 28
Additional extension period	10 years
Percentage Increase preceding lease payment amount	5.00%
Lease Period	3 years
Annual Lease fee	$ 241
Bank guarantee amount for benefit of lessor	100
Company's outstanding open purchase order commitments	$ 13,300
Bottom of range [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties on sale	3.00%
Percentage of net consideration received from the licensee	20.00%
Top of range [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties on sale	5.00%
Percentage of net consideration received from the licensee	29.50%
First three years [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage	3.00%
Three subsequent years [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage	4.00%
Seventh year [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Royalties received percentage	5.00%
2019 [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Minimum future rental payments	$ 340
2020 [Member]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Minimum future rental payments	$ 177

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Transactions With Related Parties) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Senior Management [Member]
Benefits to related parties:
Compensation and benefits to management, including benefit component of equity instrument grants	$ 2,680	$ 2,183	$ 1,912
Number of individuals to which this benefit related	6	6	6
Director [Member]
Benefits to related parties:
Compensation and benefits to management, including benefit component of equity instrument grants	$ 307	$ 356	$ 316
Number of individuals to which this benefit related	7	7	7

TRANSACTIONS AND BALANCES WITH RELATED PARTIES (Schedule of Key Management Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of transactions between related parties [abstract]
Salaries and other short-term employee benefits	$ 1,669	$ 1,808	$ 1,609
Post-employment benefits	137	136	129
Other long-term benefits	35	34	30
Share-based compensation	1,146	561	460
Benefits to key executive personnel	$ 2,987	$ 2,539	$ 2,228

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Other Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Government institutions	$ 1,337	$ 446
Other	2	140
Other receivables	$ 1,339	$ 586

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Accounts Payable and Accruals) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts payable:
Overseas	$ 3,273	$ 4,350
In Israel	1,220	1,166
Trade	4,493	5,516
Other:
Accrued expenses	792	620
Accrual for vacation and recreation pay	287	215
Payroll and related expenses	270	259
Other	14	19
Other	$ 1,363	$ 1,113

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Research and Development Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Research and development services	$ 11,609	$ 12,123	$ 5,501
Payroll and related expenses	5,704	5,097	3,475
Lab, occupancy and telephone	993	920	769
Professional fees	688	662	678
Depreciation and amortization	424	452	452
Other	390	256	302
Research and development expenses	$ 19,808	$ 19,510	$ 11,177

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Sales and Marketing Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Payroll and related expenses	$ 973	$ 817	$ 659
Marketing	291	797	600
Overseas travel	98	79	93
Sales and marketing expenses	$ 1,362	$ 1,693	$ 1,352

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of General and Administrative Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Payroll and related expenses	$ 2,510	$ 2,060	$ 2,172
Professional fees	1,142	1,298	1,144
Insurance	221	210	154
Depreciation	27	29	30
Other	535	440	484
General and administrative expenses	$ 4,435	$ 4,037	$ 3,984

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Non-Operating Income (Expenses), Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Issuance costs	$ (90)	$ (133)
Changes in fair value of warrants	1,743	(127)	207
Gain from realization of long-term investment	500
Other	244		7
Non-operating income, net	$ 2,397	$ (260)	$ 214

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Interest income and exchange differences	$ 719	$ 824	$ 469
Gain on foreign currency hedging		345	11
Financial income	$ 719	$ 1,169	$ 480

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of Financial Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Supplementary Financial Statement Information Schedule Of Sales And Marketing Expenses
Interest expense and exchange differences	$ 452		$ 8
Bank commissions	21	21	14
Financial expenses	$ 473	$ 21	$ 22

AGALIMMUNE ACQUISITION (Details) - USD ($) $ in Millions	Dec. 31, 2017	Mar. 31, 2017
Disclosure of detailed information about business combination [line items]
Total costs associated with bringing assets	$ 0.7
Total increase in intangibles	$ 6.7
Agalimmune Ltd. [Member]
Disclosure of detailed information about business combination [line items]
Initial consideration		$ 2.0
Cash consideration		$ 3.0

AMENDMENT TO BL-8040 LICENSE AND LONG-TERM LOAN (Details) - USD ($)
$ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Oct. 31, 2018

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Disclosure of detailed information about business combination [line items]

Borrowings

$ 8,733

$ 250

^[1]

Risk-free interest rate

3.00%

2.00%

Average standard deviation

61.00%

63.00%

66.00%

Loan from Kreos Capital [Member]

Disclosure of detailed information about business combination [line items]

Borrowings

$ 8,577

^[1]

Biokine Therapeutics Ltd [Member]

Disclosure of detailed information about business combination [line items]

Cash payment

$ 10,000

Issuance of ADS, value

5,000

Amount of payment in futrue milestone

$ 5,000

Percetnage of additonal upfront sublicense

10.00%

Number of warrant purchase

957,549

Exercise of price per ADS

$ 0.94

Fair value of warrant

$ 861

Risk-free interest rate

3.05%

2.69%

Average standard deviation

69.10%

68.70%

Non-operating income

$ 593

Issuance of stock

4,980,080

Biokine Therapeutics Ltd [Member] | Loan from Kreos Capital [Member]

Disclosure of detailed information about business combination [line items]

Borrowings

$ 10,000

Interest rate

9.50%

Biokine Therapeutics Ltd [Member] | Bottom of range [Member]

Disclosure of detailed information about business combination [line items]

Percentage of Reduce payment owed on sublicense receipts

20.00%

Biokine Therapeutics Ltd [Member] | Top of range [Member]

Disclosure of detailed information about business combination [line items]

Percentage of Reduce payment owed on sublicense receipts

40.00%

[1]	The loan is denominated in dollars and bears interest at an annual rate of 3.75%. The book value of the loan approximates its fair value. The loan is repayable in 60 monthly installments and is collateralized by certain lab equipment.

EVENT SUBSEQUENT TO THE BALANCE SHEET DATE (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement Line Items [Line Items]
Proceeds from shares issued		$ 3,830,000	$ 38,773,000	$ 2,183,000
Public offering [Member]
Statement Line Items [Line Items]
Number of shares issued	28,000,000
Number of warrant purchase	28,000,000
Exercise price	$ 550
Expiry	Five years
Exercise of price per ADS	$ 0.75
Proceeds from shares issued	$ 15,400,000
Net proceeds from shares issued after deducting fees and expenses	$ 14,100,000